Organoid-based modeling of platinum resistance identifies KRT17 as both a response mediator and biomarker for targeted therapy in ovarian cancer
Reichenbach, J.; Schmid, J.; Hierlmayer, S.; Zhang, T.; Piga, I.; Geweniger, S.; Fischer, J.; Davesar, A.; Vasovic, N.; Chelariu-Raicu, A.; Kraus, F.; Burges, A.; Czogalla, B.; Mayr, D.; Straub, T.; Klein, C.; Olsen, J. V.; Mahner, S.; Trillsch, F.; Kessler, M.
Show abstract
Variable platinum responses drive high mortality in high-grade serous ovarian cancer (HGSOC), but to date, there is no molecular approach to define resistance levels for clinical decision-making. Here, we developed the organoid drug resistance assay (ODR-test) with patient-derived organoids from our ovarian cancer biobank and found that all HGSOC patients develop molecular resistance under exposure to carboplatin, although with varying clinical implications. Sustained phenotypic reprogramming and cellular plasticity under carboplatin pressure emerged as a conserved mechanism irrespective of the basal resistance level. Transcriptional and proteomic analyses revealed changes in cell adhesion and differentiation in post-platinum lines as adaptive responses that drive the increase in resistance. We identified Keratin 17 (KRT17) as a mediator of developing platinum resistance and validated its function by CRISPR/Cas9 and overexpression. Additionally, we found that KRT17 expression status (K-score) is a significant negative prognostic histopathological biomarker in a large cohort (N=384) of advanced HGSOC patients. In organoids, increased KRT17 levels enhanced sensitivity to PI3K/Akt inhibitors Alpelisib and Afuresertib, highlighting the potential of KRT17 as a stratification biomarker for targeted therapies.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncology 96%
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 96%
- Differential Activity of MAPK signalling Defines Fibroblast Subtypes in Pancreatic Cancer 95%
Similar papers in this journal
- Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models 95%
- Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments 95%
- Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes 94%
Similar papers in this journal
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 95%
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 94%
- Phosphate dysregulation via the XPR1:KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer 94%
Similar papers in this journal
- A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells 96%
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 94%
- Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling 94%
Similar papers in this journal
- Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 95%
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 95%
- Aberrant transcript usage induces homologous recombination deficiency and predicts therapeutic responses 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.